Shuichi Mitsunaga

Kashiwa, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study.

Durvalumab plus gemcitabine-cisplatin versus S-1 plus gemcitabine-cisplatin in advanced biliary tract cancer: a comparative study.

Journal: ESMO gastrointestinal oncology

Published: May 21, 2026

Branched-chain amino acid catabolism is potentially deficient in pancreatic cancer with high-neural invasion.

Branched-chain amino acid catabolism is potentially deficient in pancreatic cancer with high-neural invasion.

Journal: Scientific reports

Published: January 13, 2026

Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.

Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer.

Journal: Japanese journal of clinical oncology

Published: December 28, 2025

Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.

Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.

Journal: Molecular cancer therapeutics

Published: October 05, 2025

Advances and future prospects in chemotherapy for gastrointestinal and pancreatic neuroendocrine tumors

Advances and future prospects in chemotherapy for gastrointestinal and pancreatic neuroendocrine tumors

Journal: Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology

Published: August 12, 2025

Correction: Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.

Correction: Robust circulating microRNA signature for the diagnosis and early detection of pancreatobiliary cancer.

Journal: BMC medicine

Published: April 16, 2025

Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody.

Near-Infrared Photoimmunotherapy Targeting Esophagogastric Junction Adenocarcinoma With Fully Human Anti-EpCAM Antibody.

Journal: Cancer science

Published: March 27, 2025

Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment.

Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 05, 2025

EUS-guided hepaticogastrostomy versus single balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography for malignant biliary obstruction in patients with surgically altered anatomy.

EUS-guided hepaticogastrostomy versus single balloon enteroscopy-assisted endoscopic retrograde cholangiopancreatography for malignant biliary obstruction in patients with surgically altered anatomy.

Journal: Endoscopic ultrasound

Published: December 01, 2024

Side-by-side versus stent-in-stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction.

Side-by-side versus stent-in-stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction.

Journal: DEN open

Published: November 09, 2024

A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO).

A Randomized Trial of Nutrition and Exercise Treatment in Patients With Pancreatic and Non-Small Cell Lung Cancer (NEXTAC-TWO).

Journal: Journal of cachexia, sarcopenia and muscle

Published: October 03, 2024

5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).

5-Fluorouracil metabolic pathway genes predict recurrence risk following adjuvant S-1 therapy: Results of an ancillary analysis from a phase III trial of resected biliary tract cancer (JCOG1202A1).

Journal: Journal of hepato-biliary-pancreatic sciences

Published: September 25, 2024

Showing 1-12 of 100

Last Updated: 09/26/2026